Astria Therapeutics, Inc. (ATXS) Misses Q3 EPS by 13c

Astria Therapeutics, Inc. (NASDAQ: ATXS) reported Q3 EPS of ($0.55), $0.13 worse than the analyst estimate of ($0.42). Revenue for the quarter came in at $706 thousand versus the consensus estimate of $12.8 million.

For earnings history and earnings-related data on Astria Therapeutics, Inc. (ATXS) click here.

You May Also Be Interested In

• Methode Electronics (MEI) Tops Q1 EPS by 2c; offers guidance
• Netskope, Inc. (NTSK) Tops Q2 EPS by 4c, Offers Guidance
• Hewlett Packard Enterprise (HPE) Tops Q3 EPS by 19c; raises guidance